Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer

American Journal of Pathology

Volumn 176, Issue 5, 2010, Pages 2333-2343

  Zhu, Xuegong ^a,b   Asa, Sylvia L ^a,b   Ezzat, Shereen ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 2; ISOPROTEIN; MELANOMA ANTIGEN; MELANOMA ANTIGEN A; RNA; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER TISSUE; CONTROLLED STUDY; DNA EXTRACTION; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRON; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA EXTRACTION; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; WESTERN BLOTTING;

EID: 77952066111     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.091049     Document Type: Article

References (37)

1. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, Fletcher O, Johnson N, Seal S, Stratton MR, Rahman N, Chenevix-Trench G, Bojesen SE, Nordestgaard BG, Axelsson CK, Garcia-Closas M, Brinton L, Chanock S, Lissowska J, Peplonska B, Nevanlinna H, Fagerholm R, Eerola H, Kang D, Yoo KY, Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Cox DG, Hall P, Wedren S, Liu J, Low YL, Bogdanova N, Schurmann P, Dork T, Tollenaar RA, Jacobi CE, Devilee P, Klijn JG, Sigurdson AJ, Doody MM, Alexander BH, Zhang J, Cox A, Brock IW, MacPherson G, Reed MW, Couch FJ, Goode EL, Olson JE, Meijers-Heijboer H, van den OA, Uitterlinden A, Rivadeneira F, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Hopper JL, McCredie M, Southey M, Giles GG, Schroen C, Justenhoven C, Brauch H, Hamann U, Ko YD, Spurdle AB, Beesley J, Chen X, Mannermaa A, Kosma VM, Kataja V, Hartikainen J, Day NE, Cox DR, Ponder BA: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093 (Pubitemid 47014426)
2. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover RN, Thomas G, Chanock SJ: A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007, 39:870-874
3. Meyer KB, Maia AT, O'Reilly M, Teschendorff AE, Chin SF, Caldas C, Ponder BA: Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 2008, 6:e108
4. Zhu X, Asa SL, Ezzat S: Histone Acetylated Control of Fibroblast Growth Factor Receptor 2 Intron 2 Polymorphisms and Isoform Splicing in Breast Cancer. Mol Endocrinol 2009, 23:1397-1405
5. Givol D and Yayon A: Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 1992, 6:3362-3369 (Pubitemid 23007101)
6. Yan G, Wang F, Fukabori Y, Sussman D, Hou J, McKeehan WL: Expression and transformation of a variant of the heparin-binding fibroblast growth factor receptor (flg) gene resulting from splicing of the exon at alternate 3′-acceptor site. Biochem Biophys Res Commun 1992, 183:423-430
7. Ornitz DM, Zu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M: Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996, 271:15292-15297 (Pubitemid 26195013)
8. Luo Y, Ye S, Kan M, McKeehan WL: Structural specificity in a FGF7-affinity purified heparin octasaccharide required for formation of a complex with FGF7 and FGFR2IIIb. J Cell Biochem 2006, 97:1241-1258
9. Thisse B, Thisse C, Weston JA: Novel FGF receptor (Z-FGFR4) is dynamically expressed in mesoderm and neurectoderm during early zebrafish embryogenesis. Dev Dyn 1995, 203:377-391
10. Thisse B and Thisse C: Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev Biol 2005, 287:390-402 (Pubitemid 41636772)
11. Baraniak AP, Lasda EL, Wagner EJ, Garcia-Blanco MA: A stem structure in fibroblast growth factor receptor 2 transcripts mediates cell-type-specific splicing by approximating intronic control elements. Mol Cell Biol 2003, 23:9327-9337
12. Revest JM, Spencer-Dene B, Kerr K, De Moerlooze L, Rosewell I, Dickson C: Fibroblast growth factor receptor 2-IIIb acts upstream of Shh and Fgf4 and is required for limb bud maintenance but not for the induction of Fgf8. Fgf10, Msx1, or Bmp4. Dev Biol 2001, 231:47-62 (Pubitemid 32198386)
13. Kondo T, Zhu X, Asa SL, Ezzat S: The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin Cancer Res 2007, 13:4713-4720 (Pubitemid 47294777)
14. Zhu X, Asa SL, Ezzat S: Fibroblast Growth Factor 2 and Estrogen Control the Balance of Histone 3 Modifications Targeting MAGE-A3 in Pituitary Neoplasia. Clin Cancer Res 2008, 14:1984-1996 (Pubitemid 351551107)
15. Kondo T, Zheng L, Liu W, Kurebayashi J, Asa SL, Ezzat S: Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res 2007, 67:5461-5470 (Pubitemid 46997287)
16. St Bernard R, Zheng L, Liu W, Winer D, Asa SL, Ezzat S: Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005, 146:1145-1153 (Pubitemid 40289303)
17. Simarro M, Mauger D, Rhee K, Pujana MA, Kedersha NL, Yamasaki S, Cusick ME, Vidal M, Garcia-Blanco MA, Anderson P: Fas-activated serine/threonine phosphoprotein (FAST) is a regulator of alternative splicing. Proc Natl Acad Sci USA 2007, 104:11370-11375 (Pubitemid 47175147)
18. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP: ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 2009, 33:591-601
19. Zhu X, Lee K, Asa SL, Ezzat S: Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am J Pathol 2007, 170:1618-1628 (Pubitemid 47339306)
20. Grose R and Dickson C: Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005, 16:179-186 (Pubitemid 40616115)
21. Ricol D, Cappellen D, El Marjou A, Gil-Diez-de-Medina S, Girault JM, Yoshida T, Ferry G, Tucker G, Poupon MF, Chopin D, Thiery JP, Radvanyi F: Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 1999, 18:7234-7243 (Pubitemid 30032102)
22. Bernard-Pierrot I, Ricol D, Cassidy A, Graham A, Elvin P, Caillault A, Lair S, Broet P, Thiery JP, Radvanyi F: Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor. Oncogene 2004, 23:9201-9211
23. Feng S, Wang F, Matsubara A, Kan M, McKeehan WL: Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res 1997, 57:5369-5378 (Pubitemid 27516376)
24. Zhang Y, Wang H, Toratani S, Sato JD, Kan M, McKeehan WL, Okamoto T: Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc Natl Acad Sci U S A 2001, 98:11336-11340 (Pubitemid 32928729)
25. Naimi B, Latil A, Fournier G, Mangin P, Cussenot O, Berthon P: Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate 2002, 52:245-252 (Pubitemid 34791225)
26. Mendoza S, David H, Gaylord GM, Miller CW: Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes. Cancer Genet Cytogenet 2005, 158:142-147 (Pubitemid 40417696)
27. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG, Robertson JF, Aparicio S, Ellis IO, Brenton JD, Caldas C: A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 2007, 26:1507-1516 (Pubitemid 46340809)
28. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavare S, Caldas C, Miska EA: MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007, 8:R214
29. Luqmani YA, Graham M, Coombes RC: Expression of basic fibroblast growth factor. FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 1992, 66:273-280
30. Tannheimer SL, Rehemtulla A, Ethier SP: Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2000, 2:311-320
31. Luqmani YA, Bansal GS, Mortimer C, Buluwela L, Coombes RC: Expression of FGFR2 BEK and K-SAM mRNA variants in normal and malignant human breast. Eur J Cancer 1996, 32A:518-524 (Pubitemid 26103311)
32. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL: Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993, 13:4513-4522 (Pubitemid 23220358)
33. Abbass SAA, Asa SL, Ezzat S: Altered expression of fibroblast growth factor receptors in human pituitary adenomas. J Clin Endocrinol Metab 1997, 82:1160-1166 (Pubitemid 27166658)
34. Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006, 24:1656-1664 (Pubitemid 46622136)
35. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M, Schneider C: MAGE-A tumor antigens target p53 trans-activation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 2006, 103:11160-11165 (Pubitemid 44156489)
36. Yang B, O'Herrin S, Wu J, Reagan-Shaw S, Ma Y, Nihal M, Longley BJ: Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol 2007, 127:267-275
37. Liu W, Cheng S, Asa SL, Ezzat S: The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res 2008, 68:8104-8112